Department of Surgery, and.
Department of Medical Psychology, Cancer Center Amsterdam, Amsterdam UMC, University of Amsterdam, Amsterdam.
J Natl Compr Canc Netw. 2020 Oct 1;18(10):1354-1363. doi: 10.6004/jnccn.2020.7579. Print 2020 Oct.
A relationship between quality of life (QoL) and survival has been shown for several types of cancer, mostly in clinical trials with highly selected patient groups. The relationship between QoL and survival for patients with pancreatic or periampullary cancer is unclear.
This study analyzed QoL data from a prospective multicenter patient-reported outcome registry in patients with pancreatic or periampullary carcinoma registered in the nationwide Netherlands Cancer Registry (2015-2018). Baseline and delta QoL, between baseline and 3-month follow-up, were assessed with the Happiness, EORTC Quality of Life Questionnaire-Core 30 (QLQ-C30), and QLQ-PAN26 questionnaires. The relationship between QoL and survival was assessed using Cox regression models, and additional prognostic value of separate items was assessed using Nagelkerke R2 (explained variance).
For the baseline and delta analyses, 233 and 148 patients were available, respectively. Most were diagnosed with pancreatic adenocarcinoma (n=194; 83.3%) and had stage III disease (n=77; 33.0%), with a median overall survival of 13.6 months. Multivariate analysis using baseline scores indicated several scales to be of prognostic value for the total cohort (ie, happiness today, role functioning, diarrhea, pancreatic pain, and body image; hazard ratios all P<.05) and for patients without resection (ie, overall satisfaction with life, physical and cognitive functioning, QLQ-C30 summary score, fatigue, pain, constipation, diarrhea, and body image; hazard ratios all P<.05). Except for diarrhea, all QoL items accounted for >5% of the additional explained variance and were of added prognostic value. Multivariate analysis using delta QoL revealed that only constipation was of prognostic value for the total cohort, whereas no association with survival was found for subgroups with or without resection.
In a multicenter cohort of patients with pancreatic or periampullary carcinoma, QoL scores predicted survival regardless of patient, tumor, and treatment characteristics. QoL scores may thus be used for shared decision-making regarding disease management and treatment choice.
生活质量(QoL)与生存之间的关系已在多种类型的癌症中得到证实,这些癌症主要来自于对高度选择的患者群体进行的临床试验。目前,尚不清楚胰腺癌或胰周癌患者的 QoL 与生存之间的关系。
本研究分析了在全国性荷兰癌症登记处注册的接受胰腺或胰周癌治疗的患者前瞻性多中心患者报告结局注册中心(2015-2018 年)的 QoL 数据。使用幸福感量表、EORTC 生活质量问卷核心 30 项(QLQ-C30)和 QLQ-PAN26 问卷评估基线和 3 个月随访时的 QoL 变化。使用 Cox 回归模型评估 QoL 与生存之间的关系,并使用 Nagelkerke R2(解释方差)评估单独项目的额外预后价值。
在基线和 QoL 变化分析中,分别有 233 例和 148 例患者可用于分析。大多数患者被诊断为胰腺腺癌(n=194;83.3%),且处于 III 期(n=77;33.0%),中位总生存期为 13.6 个月。使用基线评分的多变量分析表明,对于整个队列(即今天的幸福感、角色功能、腹泻、胰腺痛和身体形象)和未行切除术的患者(即对生活的总体满意度、身体和认知功能、QLQ-C30 综合评分、疲劳、疼痛、便秘、腹泻和身体形象),多个量表具有预后价值(所有 P<.05)。除腹泻外,所有 QoL 项目都解释了超过 5%的额外变异,并具有额外的预后价值。使用 QoL 变化的多变量分析显示,仅便秘对整个队列具有预后价值,而对于行或未行切除术的亚组,均未发现与生存相关。
在胰腺或胰周癌患者的多中心队列中,QoL 评分预测了生存,而与患者、肿瘤和治疗特征无关。因此,QoL 评分可用于与疾病管理和治疗选择相关的共同决策。